Power of design.

In light of the troubling results with minimally-invasive GYN surgeries, this commentary revisits the surprising oncologic advantage recently reported with robotic prostatectomies. It argues that this phase 3 trial cannot definitively answer what is was not designed to answer, namely the question of biochemical control. | Skolarikos, Eur Urol 2018